Page last updated: 2024-11-06

phenylalanylleucine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenylalanylleucine is a dipeptide composed of the amino acids phenylalanine and leucine. It is a naturally occurring compound found in various proteins and peptides. Research on phenylalanylleucine has focused on its potential roles in various biological processes, including:

- **Neurotransmitter modulation:** Studies suggest that phenylalanylleucine may influence the release and activity of neurotransmitters like dopamine and serotonin, potentially affecting mood, cognition, and behavior.

- **Antioxidant activity:** Phenylalanylleucine exhibits antioxidant properties, protecting cells from oxidative damage caused by free radicals. This effect may be attributed to its ability to scavenge reactive oxygen species.

- **Immunomodulatory effects:** Some studies indicate that phenylalanylleucine can modulate immune responses, potentially influencing the activity of immune cells and cytokine production.

- **Anti-inflammatory properties:** Phenylalanylleucine has been shown to possess anti-inflammatory properties, reducing inflammation in certain experimental models.

- **Peptide synthesis and drug delivery:** Phenylalanylleucine has been incorporated into peptide-based drug delivery systems, potentially enhancing drug efficacy and targeting.

- **Bioavailability:** Phenylalanylleucine is a relatively stable compound with good bioavailability, making it a potential candidate for therapeutic applications.

It is important to note that research on phenylalanylleucine is still ongoing, and further investigations are needed to fully understand its mechanisms of action and potential therapeutic applications. Further studies are necessary to determine its safety and efficacy in humans.'

phenylalanylleucine: RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID76808
CHEMBL ID37879
CHEBI ID91150
SCHEMBL ID1396480
MeSH IDM0103959

Synonyms (27)

Synonym
l-leucine, n-l-phenylalanyl-
PHE-LEU ,
phenylalanylleucine
CHEMBL37879 ,
3303-55-7
l-phenylalanyl-l-leucine
bdbm50027516
2-(2-amino-3-phenyl-propionylamino)-4-methyl-pentanoic acid
AKOS010420654
h-phe-leu-oh
RFCVXVPWSPOMFJ-STQMWFEESA-N
l-phe-l-leu
SCHEMBL1396480
CHEBI:91150
phenylalanyl-leucine
AS-58913
(2s)-2-[(2s)-2-amino-3-phenylpropanamido]-4-methylpentanoic acid
l-leucine, l-phenylalanyl-
J-018985
mfcd00038297
CS-0077187
(s)-2-((s)-2-amino-3-phenylpropanamido)-4-methylpentanoic acid
Q27163086
DTXSID60954651
n-(2-amino-1-hydroxy-3-phenylpropylidene)leucine
(2s)-2-[[(2s)-2-azaniumyl-3-phenylpropanoyl]amino]-4-methylpentanoate
HY-W068839
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
dipeptide zwitterionAny peptide zwitterion comprising two amino acid residues. Major structure at pH 7.3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NeprilysinRattus norvegicus (Norway rat)IC50 (µMol)20.00000.00100.17022.3000AID67343
Angiotensin-converting enzymeMus musculus (house mouse)IC50 (µMol)700.00000.01150.01150.0115AID39781
NeprilysinMus musculus (house mouse)IC50 (µMol)20.00001.00001.00001.0000AID67343
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID3978150% Inhibitory potency against Angiotensin I converting enzyme from mouse striatum.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
New carboxyalkyl inhibitors of brain enkephalinase: synthesis, biological activity, and analgesic properties.
AID233318Bitter threshold value1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID228722Bitter tasting threshold was expressed as log 1/T.1995Journal of medicinal chemistry, Jul-07, Volume: 38, Issue:14
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.
AID6734350% Inhibitory potency against enkephalinase from mouse striatum.1983Journal of medicinal chemistry, Jan, Volume: 26, Issue:1
New carboxyalkyl inhibitors of brain enkephalinase: synthesis, biological activity, and analgesic properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (37.50)18.7374
1990's1 (12.50)18.2507
2000's0 (0.00)29.6817
2010's2 (25.00)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.98 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]